Phase 4 Psoriasis Trial, Recruiting (NCT07432815)

Phase 4 Psoriasis Trial, Recruiting NCT07432815 Sponsor: Cairo University Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT07432815 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults between the ages of 18 and 60 years old
People with moderate to severe psoriasis, based on skin assessment scores measuring how much of the body is affected and how severely
People who also have moderate to severe depression and/or moderate to severe anxiety, as measured by standard questionnaire scores

Who may not be able to join:

People who are currently misusing alcohol or drugs
People who have used systemic (whole-body) psoriasis treatments, such as tablets or injections for psoriasis, within the past 3 months
People who are pregnant or breastfeeding
People who have a known allergy or sensitivity to either methotrexate or escitalopram, which are the medications used in this trial
People who have a specific form of psoriasis known as erythrodermic or pustular psoriasis
People with certain health conditions that make one of the trial medications, methotrexate, unsafe to use — for example, liver disease or a history of cancer (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +201026838866

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07432815

Sponsor: Cairo University

Phase: Phase 4

Status: Recruiting

Condition: Psoriasis

Trial contact: +201026838866

More information: https://clinicaltrials.gov/study/NCT07432815

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults between the ages of 18 and 60 years old
People with moderate to severe psoriasis, based on skin assessment scores measuring how much of the body is affected and how severely
People who also have moderate to severe depression and/or moderate to severe anxiety, as measured by standard questionnaire scores

Who may not be able to join:

People who are currently misusing alcohol or drugs
People who have used systemic (whole-body) psoriasis treatments, such as tablets or injections for psoriasis, within the past 3 months
People who are pregnant or breastfeeding
People who have a known allergy or sensitivity to either methotrexate or escitalopram, which are the medications used in this trial
People who have a specific form of psoriasis known as erythrodermic or pustular psoriasis
People with certain health conditions that make one of the trial medications, methotrexate, unsafe to use — for example, liver disease or a history of cancer (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Cairo University

Registry

ClinicalTrials.gov

Start date

1 February 2026

Est. completion

1 December 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

comparison of Percentage change in PASI score from baseline to 6 months between group A and B; Comparison between percentage change of BDI, BAI, Ham-A and Ham-D in groups A&B; Comparison of percentage of patients who achieved PASI 75%, 90% & 100% between groups A & B

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov